Lupin share price overview
One day after the company reported strong all-around performance of Lupin share price in the April-June quarter, on August 7, shares of drugmaker Lupin share price jumped over 6 percent in opening trade to reach a 52-week high of Rs 2,029.95. Lupin share price were trading on the NSE at Rs 1,976.05 at 09.20 am.
The pharmaceutical company reported a 77 percent year-over-year increase in net profit to Rs 801.3 crore in the first quarter of the fiscal year 2025. A year earlier, the company had made Rs 452.3 crore in net profit.
The first quarter of FY25 saw a 16 percent year-over-year increase in revenue, reaching Rs 5,514.30 crore from Rs 4,895.10 crore in the base period. The US business and India formulations saw double-digit sales growth, and brokerage firm Nomura believes the US sales growth was bolstered by the introduction of the bladder drug Myrbetriq, which offset a lower contribution from the bowel medication Suprep.
Q1 saw significant improvements in the company’s operational performance in addition to strong topline and bottomline growth. The EBITDA margin increased by 527 basis points year over year to a multi-quarter high of 23.3 percent.
Due in large part to the momentum we created in FY24, new products, strategic geographies, and improved performance, we had a great quarter.
together with an increase in our profitability and operating margin. With growth in sales, increased commercial and operational efficiencies, and strong compliance, we are poised for robust and sustainable growth and margin improvement.
narrative “Lupin’s Managing Director, Nilesh Gupta, stated.
According to Nomura, the company’s EBITDA margin for the quarter was 24.7 percent, excluding the Rs 75 crore it paid as settlement for the diabetes medication Glumetza. Lupin’s EBITDA margin, according to the brokerage, was also helped by lower research and development, which decreased by 5% year over year to account for 6.3 percent of total sales in the most recent quarter.
During the first quarter of the year, the pharmaceutical company achieved a new milestone by becoming net cash positive. The company’s net cash as of right now is Rs 19.50 crore, compared to net debt of Rs 1,300 crore at the end of the previous year and Rs 48o crore in Q4 FY24.
Nomura believes Lupin’s earnings growth and EBITDA margin expansion will be driven by the upcycles in all of its businesses. The firm also sees a huge opportunity arising from the hyponatremia drug Tolvaptan generic, which can present upside to its current estimates.
On Wednesday at 09:59 AM (IST), Lupin share price Ltd.’s shares saw a 3.72 percent increase in trade. During the session, the stock has experienced an intraday high of Rs 2025.0 and a low of Rs 1953.0, having opened at Rs 2011.0.
A 52-week high of Rs 2025.0 and a 52-week low of 1043.55 were quoted for the stock. 58,973 shares have exchanged hands over the counter thus far. The BSE Sensex was up 637.39 points at 79230.46 at the time this report was written, while the benchmark Nifty50 was up 233.41 points at 24225.95. 43 of the Nifty pack’s stocks had positive day trading, while 7 had negative trading.
Important Financials
The company announced consolidated sales of Rs 5668.11 crore for the quarter that ended on June 30, 2024. This represents an increase of 17.19 percent from the same quarter last year and a 13.59 percent increase from the previous quarter’s Rs 4990.04 crore. The Lupin share price reported net profit of Rs 801.31 crore for the latest quarter.
Promoter Holdings
As of June 30, 2024, the Lupin share price company’s stake was held by promoters at 46.98 percent, FIIs at 19.32 percent, and MFs at 16.23 percent.
Technical Information
The stock’s 200-Day Moving Average (DMA) was Rs. 1519.98 on August 07, while the 50-DMA was Rs. 1715.95, according to the technical charts. An upward trend is typically indicated if a stock trades above both the 50- and 200-day moving averages. Conversely, if the stock trades between these averages, it indicates that the stock may move either way. A bearish trend is indicated if the stock trades significantly below both the 50- and 200-DMAs.
ALSO READ : Today’s Google Doodle depicts the Climbing event’ at the Paris Olympics in 2024
